Francisco J. Hernandez‐Ilizaliturri

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 704 citations

Second-line Treatment, Salvage Chemotherapy, Interim Analysis +9

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 461 citations

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Asher Chanan‐Khan, Kena C. Miller, Laurie Musial et al. · Journal of Clinical Oncology · 2006 · 408 citations · Full text

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 327 citations · Full text

Immunology, Pathology, Global Phase 3 +20

Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype

Francisco J. Hernandez‐Ilizaliturri, George Deeb, Pier Luigi Zinzani et al. · Cancer · 2011 · 305 citations